Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil

Annals of Surgery

Volumn 255, Issue 1, 2012, Pages 86-94

  Van Der Wal, Gesiena E ^a   Gouw, Annette S H ^a   Kamps, Jan A A M ^a   Moorlag, Henk E ^a   Bulthuis, Marian L C ^a   Molema, Grietje ^a   De Jong, Koert P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CASPASE 3; CD31 ANTIGEN; CD34 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER PARENCHYMA; LIVER SURGERY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD31; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84155163058     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318238346a     Document Type: Article

References (59)

1. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69:271-278.
2. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38:409-413. (Pubitemid 34121969)
3. Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol. 2007;13:5857-5866. (Pubitemid 350148502)
4. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
5. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal livermetastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440-448.
6. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999;49:231-255. (Pubitemid 29525144)
7. Takeda A, Stoeltzing O, Ahmad SA, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol. 2002;9:610-616. (Pubitemid 34857976)
8. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS. 2008;116:754-770.
9. Chambers AF, GroomAC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-572. (Pubitemid 37328923)
10. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5:1779-1787. (Pubitemid 44435320)
11. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-293.
12. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-827. (Pubitemid 41753060)
13. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153.
14. Naumov GN, Folkman J, Straume O, et al. Tumor-vascular interactions and tumor dormancy. APMIS. 2008;116:569-585.
15. Peeters CF, de Waal RM, Wobbes T, et al. Metastatic dormancy imposed by the primary tumor: does it exist in humans? Ann Surg Oncol. 2008;15: 3308-3315.
16. Peeters CF, Westphal JR, de Waal RM, et al. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004;%20;112:554-559. (Pubitemid 39425934)
17. Peeters CF, deWaal RM, Wobbes T, et al. Outgrowth of human livermetastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer. 2006;119:1249-1253. (Pubitemid 44258796)
18. Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer. 2008;44:1835-1840.
19. Zeng W, Gouw AS, van den Heuvel MC, et al. Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. Ann Surg Oncol. 2010;17:1564-1571.
20. Zeng W, Gouw AS, van den Heuvel MC, et al. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology. 2008;48:1517-1527.
21. Gouw AS, van den HeuvelMC, Boot M, et al. Dynamics of the vascular profile of the finer branches of the biliary tree in normal and diseased human livers. J Hepatol. 2006;45:393-400. (Pubitemid 44142109)
22. van den Heuvel MC, de Jong KP, van derHorst ML, et al. Impaired regeneration of biliary cells in human chronic liver allograft rejection. Special emphasis on the role of the finest branches of the biliary tree. Liver Transpl. 2004;10:28-35.
23. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314:15-23. (Pubitemid 37409909)
24. Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 1997;430:195-207. (Pubitemid 27151929)
25. Lalor PF, Lai WK, Curbishley SM, et al. Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol. 2006;12:5429-5439. (Pubitemid 44501799)
26. Theuerkauf I, Zhou H, Fischer HP. Immunohistochemical patterns of human liver sinusoids under different conditions of pathologic perfusion. Virchows Arch. 2001;438:498-504. (Pubitemid 32449059)
27. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 2006;66:11089-11093.
28. Yamamoto M, Kikuchi H, Ohta M, et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 2008;68:9754-9762.
29. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11:215-221.
30. Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res. 2009;15:3648-3653.
31. Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res. 2010;70:1804-1813.
32. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. NatMed. 2003;9:936-943. (Pubitemid 36889938)
33. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol. 2009; 175:2159-2170.
34. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009;69:1324-1333.
35. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol. 2004;204:1-10. (Pubitemid 39214476)
36. Sie M, Wagemakers M, Molema G, et al. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg. 2009;110:147-155.
37. Wada H, Nagano H, Yamamoto H, et al. Combination therapy of interferonalpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep. 2007;18:801-809.
38. Phelps ED, Updike DL, Bullen EC, et al. Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2006;290:C352-C361.
39. Shyu KG, Liang YJ, Chang H, et al. Enhanced expression of angiopoietin-2 and the Tie2 receptor but not angiopoietin-1 or the Tie1 receptor in a rat model of myocardial infarction. J Biomed Sci. 2004;11:163-171. (Pubitemid 38269806)
40. Wulff C, Wilson H, Largue P, et al. Angiogenesis in the human corpus luteum: localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J Clin Endocrinol Metab. 2000;85:4302-4309. (Pubitemid 32055391)
41. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology. 2003;37:1105-1113. (Pubitemid 36538687)
42. Bognar G, Ledniczky G, Toth KE, et al. Prognostic role of vascularisation and proliferation in rectal cancer with liver metastasis. Hepatogastroenterology. 2009;56:367-371.
43. Peeters CF, deWaal RM, Wobbes T, et al. Outgrowth of human livermetastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer. 2006;119:1249-1253. (Pubitemid 44258796)
44. Pamecha V, Levene A, Grillo F, et al. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer. 2009; 100:617-622.
45. Anjomshoaa A, Nasri S, Humar B, et al. Slow proliferation as a biological feature of colorectal cancer metastasis. Br J Cancer. 2009;101:822-828.
46. Rmali KA, Puntis MC, Jiang WG. Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis. 2007;9:3-14. (Pubitemid 44869671)
47. Rasheed S, McDonald PJ, Northover JM, et al. Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract. 2008;204:501-510.
48. Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114:4583-4591.
49. Burdick MM, McCaffery JM, Kim YS, et al. Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. Am J Physiol Cell Physiol. 2003;284:C977-C987. (Pubitemid 36336954)
50. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010.
51. Laferriere J, Houle F, Taher MM, et al. Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem. 2001;276:33762-33772.
52. Tremblay PL, Auger FA, Huot J. Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases. Oncogene. 2006;25:6563-6573. (Pubitemid 44646184)
53. Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis. Acta Histochem. 2010;112:3-25.
54. Smith CW. Possible steps involved in the transition to stationary adhesion of rolling neutrophils: a brief review. Microcirculation. 2000;7: 385-394.
55. Cascone I, Napione L, Maniero F, et al. Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol. 2005;170:993-1004. (Pubitemid 41306298)
56. Brodt P, Fallavollita L, Bresalier RS, et al. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer. 1997;71:612-619. (Pubitemid 27239372)
57. Khatib AM, Kontogiannea M, Fallavollita L, et al. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 1999;59:1356-1361. (Pubitemid 29136269)
58. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575-585.
59. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591.